CoChat

KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue

Mostert, Bianca, Jiang, Yuqiu, Sieuwerts, Anieta M., Wang, Haiying, Bolt‐de Vries, Joan, Biermann, Katharina, Kraan, Jaco, Lalmahomed, Zarina, van Galen, Anne, de Weerd, Vanja, van der Spoel, Petra, Ramírez‐Moreno, Raquel, Verhoef, Cornelis, IJzermans, Jan N.M., Wang, Yixin, Gratama, Jan‐Willem, Foekens, John A., Sleijfer, Stefan, Martens, John W.M. · 2013 · International Journal of Cancer
Cited by 130

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Although anti‐EGFR therapy has established efficacy in metastatic colorectal cancer, only 10‐20% of unselected patients respond. This is partly due to KRAS and BRAF mutations, which are currently assessed in the primary tumor. To improve patient selection, assessing mutation status in circulating tumor cells (CTCs), which possibly better represent metastases than the primary tumor, could be advantageous. We investigated the feasibility of KRAS and BRAF mutation detection in colorectal CTCs by comparing three sensitive methods and compared mutation status in matching primary tumor, liver metastasis and CTCs. CTCs were isolated from blood drawn from 49 patients before liver resection using CellSearch™. DNA and RNA was isolated from primary tumors, metastases and CTCs. Mutations were assessed by co‐amplification at lower denaturation temperature‐PCR (Transgenomic™), real‐time PCR (EntroGen™) and nested Allele‐Specific Blocker (ASB‐)PCR and confirmed by Sanger sequencing. In 43 of the 49 patients, tissue RNA and DNA was of sufficient quantity and quality. In these 43 patients, discordance between primary and metastatic tumor was 23% for KRAS and 7% for BRAF mutations. RNA and DNA from CTCs was available from 42 of the 43 patients, in which ASB‐PCR was able to detect the most mutations. Inconclusive results in patients with low CTC counts limited the interpretation of discrepancies between tissue and CTCs. Determination of KRAS and BRAF mutations in CTCs is challenging but feasible. Of the tested methods, nested ASB‐PCR, enabling detection of KRAS and BRAF mutations in patients with as little as two CTCs, seems to be superior.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.27987

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 130

Metadata

Authors
Mostert, B., Jiang, Y., Sieuwerts, A. M., Wang, H., Bolt‐de Vries, J., Biermann, K., Kraan, J., Lalmahomed, Z., van Galen, A., de Weerd, V., van der Spoel, P., Ramírez‐Moreno, R., Verhoef, C., IJzermans, J. N. M., Wang, Y., Gratama, J., Foekens, J. A., Sleijfer, S., & Martens, J. W. M.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2013-02-09
Volume
133
Issue
1
Pages
130-141
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W1792294722
Cited by
130
References
17
FWCI
6.68
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. https://app.cochat.ai/papers/10.1002/ijc.27987
The paper
Mostert, B., Jiang, Y., Sieuwerts, A. M., Wang, H., Bolt‐de Vries, J., Biermann, K., Kraan, J., Lalmahomed, Z., van Galen, A., de Weerd, V., van der Spoel, P., Ramírez‐Moreno, R., Verhoef, C., IJzermans, J. N. M., Wang, Y., Gratama, J., Foekens, J. A., Sleijfer, S., & Martens, J. W. M. (2013). KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. International Journal of Cancer. https://doi.org/10.1002/ijc.27987

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.